Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
Status:
Unknown status
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, single arm study. The study group will be compose of
NVAMD patients who had partial or complete failure responding to initial bevacizumab or
ranibizumab treatment of 3-6 monthly intravitreal injections. The patients in the study
groups will receive 5 intravitreal injections of aflibercept 2mg/0.05ml at specific visits.
Aflibercept will be provided for total period of 24 weeks.